Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Eleclazine on QT Interval in Long QT-3 Syndrome
2014-000042-30Phase 3Terminated
- Sponsor
- Gilead Sciences
- Start
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-blind, single-arm trial of eleclazine in long QT syndrome (LQTS), sponsored by Gilead Sciences. Primary endpoint: Primary endpoint: change in mean daytime QTcF interval at Week 24. Started Nov 2014; status: terminated.
02
Drugs
eleclazine
03
Conditions
long QT syndrome (LQTS)
Beyond the preview
Go deeper on 2014-000042-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000042-30.